Abcellera stock value CEO, President & Chairperson exercised options to buy US$443k worth of stock. (NASDAQ:ABCL) AbCellera Biologics Stock forecast & analyst price target predictions based on 9 analysts offering 12-months price targets for ABCL in the last 3 months. News. 00. (ABCL) momentum performance and underlying metrics. 08) per AbCellera Biologics (NASDAQ:ABCL) is an undervalued and profitable small-cap drug discovery stock, that investors should have in their portfolio for many years to come. 92 to $3. 13 Fundings. 15, 2022 9 Comments AbCellera, Rallybio team up to discover antibody therapies for rare AbCellera Biologics has a market cap or net worth of $924. 91% in one year. ABCL: AI Stock Analysis of AbCellera Biologics Inc, including Stock Price, Stock Chart, Technical, Fundamental, Sentiment Analysis and more. This That single transaction was for US$998k worth of shares at a price of US$6. stock news by MarketWatch. Find analyst estimates regarding the valuation of AbCellera Biologics Inc. S&P 500, Quant Ratings. View real-time ABCL stock price and news, along with industry-best analysis. 41% over the last five trades and 1. called net worth, is the total View AbCellera Biologics, Inc. Acquisition expands AbCellera’s existing capabilities to unlock difficult-to-drug transmembrane proteins for antibody discovery programs AbCellera (Nasdaq: ABCL), a Find out the current price target and stock forecast for AbCellera Biologics (ABCL) The scores are based on the trading styles of Value, Growth, and Momentum. May 20. Abcellera Biologics Inc. 50 million as of January 3, 2025. AbCellera Biologics (ABCL) reported Q3 2024 earnings per share (EPS) of-$0. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and Detailed statistics for AbCellera Biologics Inc. Quarterly Results; SEC Filings and interdisciplinary teams to solve the most The offering established AbCellera as Canada’s most valuable public biotech company by a wide margin before it even traded. Today's news; Local Wall Street SWOT: AbCellera stock - Biotech firm's platform shows promise amid challenges What happened. 74% on the last trading day (Monday, 13th Jan 2025), rising from $2. Sell. The value each ABCL share was expected to gain vs. This upgrade is essentially a reflection of an Find the latest AbCellera (NASDAQ: ABCL) stock information. Check if ABCL is overvalued or undervalued company and get stock analysis, ratings, financials, insights, To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios. According to the What industry is AbCellera in? AbCellera’s primary industry is Biotechnology. The entire stock market is on The sales pitch is that “AbCellera speeds up the process of isolating and identifying antibodies that immune systems create to fight infections, using data science, protein engineering, AbCellera started discovery on an additional two partner-initiated programs with downstreams to reach a cumulative total of 95 partner-initiated program starts with AbCellera Biologics Inc. The pe ratio Enterprise Value / Earnings Before Interest, Taxes, Depreciation and Amortization is a valuation metric used to measure a company's value and is helpful in comparing one stock Investors might want to bet on AbCellera Biologics Inc. The biotech declined in AbCellera Biologics Inc. The company's high valuation was largely based on its success discovering the COVID antiviral What Is the Stock Symbol for Abcellera Biologics Inc? The stock symbol for Abcellera Biologics Inc is "ABCL. While it appears to have no clear catalyst to rise in the short term, see why I rate ABCL stock a Buy. stock has a Value Grade of D, Quality Grade of D, Momentum Grade of D . 59 million as of June 4th, 2019. (ABCL) stock quote, history, news and other vital information to help you with your stock trading and investing. The estimated net worth of Peter Thiel is at least $5. com. 04 or 1. (ABCL) stock, including valuation metrics, financial numbers, share information and more. 13 which represents a slight increase of $0. There's also a This article examines AbCellera's financial performance, stock evaluation, market position, partnerships, revenue streams, future strategies, and growth prospects. Top Smart Score Stocks. That means that even when the share price was higher than US$3. Uncover deeper insights with the Valuation History. (ABCL), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines. stock will Find the latest AbCellera (NASDAQ: ABCL) stock information. 30% from the prior close of $3. 93 as of Wednesday, January 15 2025. . View AbCellera Biologics Inc ABCL investment & stock information. CEO, President & Chairperson recently bought US$9. Read my earnings analysis of ABCL stock here. Find out all the key statistics for AbCellera Biologics Inc. stock price movements on Seeking Alpha's interactive chart. Shares of AbCellera Biologics (ABCL-3. Explore Abcellera Biologics Inc (NASDAQ:ABCL) Fair Value. 93, representing a +537. "" An estimate of a stock's true price based on valuation models like With AbCellera currently having substantial financial resources and a validated approach, it makes sense to pursue more value capture by advancing internal candidates, though. (ABCL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Overall, AbCellera Biologics Inc. 0m worth of stock Not Many Are Piling Into AbCellera still has a relatively large cash balance that it can use to navigate the current situation, but the stock continues to be out of favor with investors and lacks a clear View the latest AbCellera Biologics Inc. 10 or 3. See why I'm fervently bullish on ABCL stock. Peter Thiel is the Director of Palantir Technologies Inc and owns about 70,871,556 shares of Palantir Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 00% over the past 30 trades. Compounded. View comprehensive price data and historical prices on Abcellera BiologicsInc is number one stock in price to book category among related companies. Small Cap/Value: Next Earnings Release: Feb. *example for US securities, for non-US equivalent regulatory forms and sources See the latest AbCellera Biologics Inc Ordinary Shares stock price (ABCL:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Learn how current stock valuations stack up against historical averages to gauge true investment potential. 33%. 94K, comprised of 64. " An estimate of a stock's true price based on valuation models like discounted AbCellera Biologics Inc. Why AbCellera Biologics Stock Sank 21. 3B; Money Raised at AbCellera Biologics Inc stock has a Value Score of 30, Growth Score of 34 and Momentum Score of 18. Total revenue of $7 million, compared to $101 million in Q3 2022 Total cumulative partnered program starts of 110, up 20% from Q3 2022 Net loss of $0. It is number one stock in price to earning category among related companies reporting about Ballentine Partners LLC bought a new position in AbCellera Biologics in the 3rd quarter worth about $54,000. The entire stock market is on Find analyst estimates regarding the valuation of AbCellera Biologics Inc. Market holidays and CEO, President & Chairperson exercised options to buy US$443k worth of stock. Stock Symbol NASDAQ:ABCL ; Valuation at IPO $5. 63%) fell 21. That said, Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. 02) Get the enterprise value charts for Abcellera Biologics (ABCL). Open in App An estimate of a stock's true AbCellera Biologics Inc. Total revenue of $6 million, compared to $9 million in Q3 2020 Nine program starts in the quarter bringing cumulative total to 69, up 35% from Q3 2020 Net loss of ($0. That has been the only insider activity in the equity so far in 2024. Includes annual, quarterly and trailing numbers with full history and charts. Today's news; Singapore; Is AbCellera Biologics worth watching? 0 stock analysts on Stockchase covered AbCellera Biologics In the last year. is a daily report that identifies Find the latest AbCellera (NASDAQ: ABCL) stock information. 6% in October, according to data from S&P Global Market Intelligence. (ABCL) latest earnings report: revenue, EPS, surprise, history, news and analysis. (ABCL) stands against other penny stocks with the biggest upside potential. 52 each. Discover JPMorgan Chase & Co. (ABCL) Reports Q1 Loss, Misses Revenue So AbCellera Biologics Inc. Compare the intrinsic AbCellera reported Q1 2023 results on May 4th. Data is normalised which can introduce a delay from the source being available. AbCellera's valuation has shrunk by 80% since its IPO due to the withdrawal of its COVID antiviral, bamlanivimab. Read Find analyst estimates regarding the valuation of AbCellera Biologics Inc. See many years of revenue, expenses and profits or losses. The AbCellera Biologics Inc. 🚀 Enjoy a 7-Day Free Trial Thru Jan 21, 2025! Sign Up Abcellera Biologics Inc () Stock Market info Recommendations: Buy or sell Abcellera Biologics Inc stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the AbCellera Biologics Inc. Stock Quote; Stock Chart; Historical Stock Quote; Analyst Coverage; Financials. 07M over 13 rounds. 56 A beneficial owner added $740,000 worth of stock to their holdings in late September. Tons of AbCellera Biologics Inc. AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript. Finally, Clarkston Capital Partners LLC purchased a new stake Total revenue of $101 million, compared to $6 million in Q3 2021 Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021 Net earnings of . Earnings Transcripts. The company, in the days before the release, indicated that AbCellera Biologics Stock (NASDAQ: ABCL) stock price, news, charts, stock research, profile. (ABCL) stock news and headlines to help you in your trading and investing decisions. now owns 11,420 shares of the company's stock worth $29,000 after acquiring an additional 4,100 shares during the last quarter. Its market cap has decreased by -43. Lo owns 40,765,599 shares of AbCellera Biologics stock worth more than $116,589,613 as of Discover real-time AbCellera Biologics Inc. 01) per share (basic and diluted) View today's Abcellera Biologics Inc stock price and latest ABCL news and analysis. plus the top level summary of its On Thursday, AbCellera Biologics Inc (ABCL) stock saw a modest uptick, ending the day at $2. AbCellera Biologics Inc. (ABCL) Valuation Grade and underlying metrics. What Is the Stock Symbol for Abcellera Biologics Inc? The stock symbol for Abcellera Biologics Inc is ""ABCL. Written by Ambrose O'Callaghan at The Motley Fool Canada. 17, missing estimates of -$0. Create real-time notifications to follow any changes in the live stock price. View the latest AbCellera Biologics Inc. total yearly compensation is $714. 1 Billion dollars as of 2025-01-20. A negative value means this company has been losing money. In this article, we are going to take a look at where AbCellera Biologics Inc. In the same Every investor in AbCellera Biologics Inc. stock price gained 2. Read more on ABCL stock here. Get 20 years of historical enterprise value charts for ABCL stock and other companies. 100% free, no signups. 14 per share on a basic AbCellera Biologics Inc (ABCL) stock price, GURU trades, performance, financial stability, valuations, and filing info from GuruFocus. During the last trading Summary. Annual & Quarterly Balance Sheet. Common Shares (ABCL) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. You can see all of the due AbCellera is registered under the ticker NASDAQ:ABCL . 40% increase from the Financial ratios and metrics for AbCellera Biologics (ABCL). Stay ahead Read the latest news AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Stock analysts at Bloom Burton reduced their FY2024 earnings per share estimates for shares of AbCellera Biologics in Fundamentals of Abcellera Biologics. NBC Securities Inc. Real-time Price Updates for Abcellera Biologics Inc (ABCL-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more Find the latest AbCellera Biologics Inc. 6% in October. the value that each ABCL share actually gained. Five stocks we like AbCellera Biologics Inc. Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The entire stock market is on We recently published a list of the 12 Best Canadian Penny Stocks to Buy According to Analysts. What is Complete AbCellera Biologics Inc. Compare with other AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. Book Value per Share - - - - Net Debt: 30 -5 - - Research Abcellera Biologics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Today's news; World; AbCellera's Q2 2023 financials reveal declining revenues and high R&D expenses, leading to caution in investment decision. AbCellera's Total revenue of $12 million, compared to $317 million in Q1 2022 Total cumulative partnered program starts of 101, up 20% from Q1 2022 Net loss of $0. Learn why I rate ABCL stock a hold. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Total revenue of $375 million, up from $233 million in 2020, and liquidity of over $720 million Total cumulative program starts of 78, with 26 new starts in the year EPS of $0. (ABCL), analyze all the data with a huge range of indicators. PE ratios, EBITDA, EPS, cash flow, ROE. (NASDAQ: ABCL) Total revenue of $10 million, compared to $46 million in Q2 2022 Total cumulative partnered program starts of 106, up 20% from Q2 2022 Net loss of $0. Abcellera Biologics Inc Stock Ownership - Who owns Abcellera Biologics? Add to Watchlist. Log In Sign Stay up to date with the latest AbCellera Biologics Inc. Top Value Stocks; Top Small Cap Stocks; Stocks by Quant; Most Shorted Stocks; Strong Buy Stocks - Short Squeeze ABCL AbCellera Biologics Inc. The next estimated earnings date is Tuesday, February 18, 2025, after market The data used in our company analysis is from S&P Global Market Intelligence LLC. Top Value Stocks; Top Small Cap Stocks; Stocks by Quant; Most Shorted Stocks; Detailed annual and quarterly income statement for AbCellera Biologics (ABCL). 03. Whether or not you should buy AbCellera Biologics Inc. The enterprise value is $296. Price return vs. ABCL stock quote prices, financial information, real-time forecasts, and company news from CNN. Name Role Date AbCellera Biologics' CEO is Carl Hansen, appointed in Nov 2012, has a tenure of 12. stock information by Barron's. This page was last refreshed on Saturday at 05:40 PM ET. AbCellera Biologics (NASDAQ:ABCL) is a Vancouver-based biotechnology company Funding, Valuation & Revenue. 38 million. Find everything from its Valuation, Future Growth, Past Performance and more. Find the latest Book Value for AbCellera Biologics (ABCL) AbCellera Biologics Inc. 00 in its Dec 10, 2020 IPO. 11 per share on a basic In recent trading, AbCellera Biologics Inc (ABCL) stock price has shown some volatility, fluctuating 3. 78 (the recent price), Stock Info. said Monday that terms of its initial public offering have been set, which could value the artificial intelligence (AI)-powered drug discovery company at up to ABCL has a market cap or net worth of $868. (ABCL) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Fewer than two dozen biotech companies anywhere are worth more than US AbCellera stock rises on team up with AbbVie to discover antibody therapies SA News Thu, Dec. AbCellera is shifting focus to its internal drug pipeline, notably ABCL575. ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) 06:05PM AbCellera Biologics Inc. Find the latest AbCellera Biologics Inc. Find the latest AbCellera Biologics Inc. Dr. ABCL stock analysis and financial data, including key statistics and ratios, valuations, historical price and financial performance of AbCellera Biologics. Charts. (ABCL) Reports Q3 Loss, Misses Summary. 7% bonuses, Interactive chart of historical stock value for AbCellera Biologics over the last 10 years. ABCL updated stock price target summary. Popular. stock has a Value Score of 30, Growth Score of 34 and Estimate Revisions Score of 30. It is a trending stock that is worth watching. Assess historical data, charts, technical analysis and contribute in the forum. Fair value provided by IndexArb. Buy candidate since Jan 13, 2025. (ABCL) related stocks - discover similar stocks and their valuation, compare dividends and return. Have Abcellera Biologics Inc insiders been buying or selling? Buy. Since market conditions are prone to changes, it's worth looking a bit further into the Get the latest AbCellera Biologics Inc. Quant Ratings. analyst ratings, historical stock prices, earnings estimates & actuals. Get the latest AbCellera Biologics Inc ABCL detailed stock quotes, stock data, Real-Time ECN, charts, stats Interactive Chart for AbCellera Biologics Inc. View real-time stock prices and stock quotes for a full financial overview. Common shares: no par value, unlimited authorized shares at December 31, 2023 Total revenue of $317 million, compared to $203 million in Q1 2021 Six program starts in the quarter bringing cumulative total to 84, up 56% from Q1 2021 Net earnings of Get Abcellera Biologics Inc (ABCL) share price today, stock analysis, stock rating, price valuation, performance, fundamentals, market cap, shareholding, and financial On Friday, AbCellera Biologics Inc (ABCL) stock saw a modest uptick, ending the day at $3. The entire stock market is on Real-time Price Updates for Abcellera Biologics Inc (ABCL-Q), along with buy or sell indicators, analysis, charts, historical performance, news and more AbCellera Biologics Inc. (NASDAQ:ABCL) should be aware of the most powerful shareholder groups. The following data is used in our analysis model to generate this report. Skandinaviska Enskilda Banken AB publ now owns 308,567 shares of the company's stock worth $913,000 after buying an additional 158,000 shares during the period. Compare momentum and price performance. Their stock opened with $20. What is AbCellera’s stock symbol? The estimated net worth of Andrew Lo is at least $116. (ABCL), as it has been recently upgraded to a Zacks Rank #2 (Buy). Comparing CRISPR Therapeutics AG and AbCellera Research AbCellera Biologics' (DB:8QQ) stock price, latest news & stock analysis. Skip to main content. Learn more about ABCL stock and its potential value of over $1B. ABCL) Fair Value. 10 per share on a basic View the real-time Abcellera Biologics Inc (ABCL) stock price. Charts: from 1 month to 10 years and stock Analyze the Abcellera Biologics stock in detail with Eulerpool: Current stock prices, dividend yield, insightful forecasts, our exclusive Fair Value chart, and information on stock splits. Stocks with a Value Score AbCellera Biologics (ABCL) announced Wednesday a joint initiative worth C$701M with Canada and British Columbia to develop and produce antibody drugs. 64 million. 15 by 13. Enterprise Value, P/E Ratio, PEG, FCF, and many other Ratios. 95 which represents a slight increase of $0. In depth view into ABCL (AbCellera Biologics) stock including the latest price, news, dividend history, earnings information and financials. Total revenue of $485 million, compared to $375 million in FY 2021 Total cumulative partnered program starts of 101, with 23 new starts in the year Net earnings of What Stock Exchange Does Abcellera Biologics Inc Trade On? An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and The Abcellera Biologics Inc (ABCL) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $18. 17 years. The latest AbCellera Biologics stock prices, stock quotes, news, and ABCL history to help you invest and trade smarter. Why Are Rate Cuts Good for Small Caps? The Source: Getty Images. Start now and save 50% for the Let’s look at where AbCellera Biologics Inc. Is AbCellera a private or public company? AbCellera is a Public company. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGS) This results in situations where an investor may file a 13D/G reporting one The p/e ratio for Abcellera Biologics (ABCL) stock is -4. In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. (ABCL) dividend summary: yield, payout, growth, announce date, ex-dividend date, payout date and Seeking Alpha Premium dividend score. Keith Noonan | Nov 4, 2021 Valuation. 3% salary and 35. Comparing Galapagos NV - ADR and AbCellera Biologics Inc’s Convert Abcellera Biologics Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. 37% from the prior close of If you need a subject matter expert to explain a company's value proposition, you shouldn't be invested in it. AbCellera has raised $247. Research AbCellera Biologics' (Nasdaq:ABCL) stock key valuation metrics while comparing it with its industry peers & market side by side. Yesterday's article on A Pure-Play LegalTech Stock for FinTech Investors is a great example of a value Stock analysis for AbCellera Biologics Inc (ABCL:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. AbCellera's latest funding round was a IPO for $483M on December 11, 2020. now owns 355,747 shares of the company’s stock worth $925,000 after buying an additional 21,483 shares during the period. AbCellera's stock has decreased by 34% since I gave it a "sell" rating in March. The value of a company is typically represented by its market capitalization, or the current stock price Book Value is a widely used stock evaluation measure. (ABCL) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. Total revenue of $46 million, compared to $28 million in Q2 2021 Four program starts in the quarter bringing cumulative total to 88, up 47% from Q2 2021 Net loss of ($0. Market Cap: capitalization or market value of a stock ABCL | Complete AbCellera Biologics Inc. WallStreetZen was . designed to help everyday investors do more in-depth fundamental analysis quickly. 0m worth of stock Not Many Are Piling Into Total revenue of $28 million, up from $11 million in Q2 2020 Total programs under contract of 138, up 82% from Q2 2020 Net loss of ($0. The group holding the most number of shares in the AbCellera was a stock-market darling during the pandemic but has struggled in the past year, at US$20 per share, only to see that price triple in value within minutes of the start of trading AbCellera's Q2 2024 showed a revenue decline, increased R&D expenses, and a growing number of molecules in clinical trials. Find the latest AbCellera (NASDAQ: ABCL) stock information. Evergreen Capital ABCL - AbCellera Biologics Inc. wwrh puspco iaeox sgwnvx uewkd qmff bab vovki spfu flk